Tumor lysis syndrome: Difference between revisions

(Minor edit)
No edit summary
Line 5: Line 5:
**Potassium
**Potassium
**Phosphate
**Phosphate
***Binds Ca > hypocalcemia
***Binds Ca causing [[hypocalcemia]]
**Uric acid (converted from nucleic acids)
**Uric acid (converted from nucleic acids)


==Risk Factors==
===Risk Factors===
#High cell proliferation rate
#High cell proliferation rate
#Large tumor burden (LDH) > 1500 IU/L, WBC ≥ 50 x 103 cells/L
#Large tumor burden (LDH) > 1500 IU/L, WBC ≥ 50 x 103 cells/L
Line 14: Line 14:
#Tumor infiltration of the kidney
#Tumor infiltration of the kidney


==Cairo-Bishop Definition==
===Cairo-Bishop Definition===
*Laboratory Tumor Lysis Syndrome
*Laboratory Tumor Lysis Syndrome
**Abnormality in 2 or more of the following, occurring w/in 3d before or 7d after chemo:
**Abnormality in 2 or more of the following, occurring w/in 3d before or 7d after chemo:
Line 30: Line 30:
#Hyperuricemia
#Hyperuricemia
##N/V, lethargy, renal failure
##N/V, lethargy, renal failure
#Hyperkalemia
#[[Hyperkalemia]]
##Most immediate life-threatening element (due to dysrrhythmias)
##Most immediate life-threatening element (due to dysrrhythmias)
#Hyperphosphatemia
#[[Hyperphosphatemia]]
##May combine w/ Ca to precipiate in renal tubules
##May combine w/ Ca to precipiate in renal tubules
#Hypocalcemia
#[[Hypocalcemia]]
##Anorexia, cramping, tetany, confusion, seizures, V-tach/torsades
##Anorexia, cramping, tetany, confusion, seizures, [[V-tach]]/[[torsades]]
#Acute renal failure
#[[Acute Renal Failure]]
##Most common cause of morbidity
##Most common cause of morbidity
##Usually results from uric acid precipitation within renal tubules
##Usually results from uric acid precipitation within renal tubules
Line 47: Line 47:
#LDH
#LDH
#UA  
#UA  
#ECG
#[[ECG]]
##HyperK, hypoCa
##HyperK, hypoCa
   
   
==Imaging==
===Imaging===
*Avoid IV contrast
*Avoid IV contrast


Line 57: Line 57:
##Goal urine output is 3L in 24hr
##Goal urine output is 3L in 24hr


===Hypocalcemia===
===[[Hypocalcemia]]===
*≤7 or 25% dec in baseline
*≤7 or 25% dec in baseline
**Treat only if symptomatic (increased Ca leads to increased Ca/phos deposition), such as widened QRS or ventricular arrhythmias
**Treat only if symptomatic (increased Ca leads to increased Ca/phos deposition), such as widened QRS or ventricular arrhythmias
**Calcium gluconate 50-200mg IV
**Calcium gluconate 50-200mg IV


===Hyperphosphatemia===
===[[Hyperphosphatemia]]===
*≥4.5 or 25% increase; ≥ 6.5mg/dL in children
*≥4.5 or 25% increase; ≥ 6.5mg/dL in children
**IV insulin & glucose
**IV insulin & glucose
Line 80: Line 80:
****Urate oxidase converts uric acid to allantoin (5-10x more soluble)
****Urate oxidase converts uric acid to allantoin (5-10x more soluble)


===Hyperkalemia===
===[[Hyperkalemia]]===
*Only give Ca for cardiovascular instability (e.g.ventricular arrhythmias, widened QRS)
*Only give Ca for cardiovascular instability (e.g.ventricular arrhythmias, widened QRS)
**Giving Ca leads to increased Ca/phos deposition which leads to renal failure
**Giving Ca leads to increased Ca/phos deposition which leads to renal failure

Revision as of 12:24, 7 January 2014

Background

  • Associated w/ treatment of ALL, Burkitt lymphoma, NHL
    • Rarely observed in solid tumros or without prior therapy
  • Rapid turnover of tumor cells (spontaneously or after Rx) leading to release of:
    • Potassium
    • Phosphate
    • Uric acid (converted from nucleic acids)

Risk Factors

  1. High cell proliferation rate
  2. Large tumor burden (LDH) > 1500 IU/L, WBC ≥ 50 x 103 cells/L
  3. Extensive BM involvement
  4. Tumor infiltration of the kidney

Cairo-Bishop Definition

  • Laboratory Tumor Lysis Syndrome
    • Abnormality in 2 or more of the following, occurring w/in 3d before or 7d after chemo:
  1. Uric acid ≥ 8 mg/dL or 25% increase from baseline
  2. Potassium ≥ 6mEq/L or 25% increase from baseline
  3. Phosphate ≥ 4.5 mg/dL or 25% increase from baseline (≥ 6.5 for children)
  4. Calcium ≤ 7 mg/dL or 25% decrease from baseline
  • Clinical Tumor Lysis Syndrome
    • Laboratory tumor lysis syndrome plus 1 or more of the following:
  1. Cr > 1.5 times upper limit of age-adjusted reference range
  2. Cardiac dysrhythmia or sudden death
  3. Seizure

Clinical Features

  1. Hyperuricemia
    1. N/V, lethargy, renal failure
  2. Hyperkalemia
    1. Most immediate life-threatening element (due to dysrrhythmias)
  3. Hyperphosphatemia
    1. May combine w/ Ca to precipiate in renal tubules
  4. Hypocalcemia
    1. Anorexia, cramping, tetany, confusion, seizures, V-tach/torsades
  5. Acute Renal Failure
    1. Most common cause of morbidity
    2. Usually results from uric acid precipitation within renal tubules

Work Up

  1. CBC
  2. Chemistry
  3. Calcium, phosphate
  4. Uric Acid
  5. LDH
  6. UA
  7. ECG
    1. HyperK, hypoCa

Imaging

  • Avoid IV contrast

Treatment

  1. Agressive hydration
    1. Goal urine output is 3L in 24hr

Hypocalcemia

  • ≤7 or 25% dec in baseline
    • Treat only if symptomatic (increased Ca leads to increased Ca/phos deposition), such as widened QRS or ventricular arrhythmias
    • Calcium gluconate 50-200mg IV

Hyperphosphatemia

  • ≥4.5 or 25% increase; ≥ 6.5mg/dL in children
    • IV insulin & glucose
    • Phosphate Binder - Aluminum hydroxide (50-150mg/kg PO q4-6h) - limited effect
    • Dialysis if refractory

Hyperuricemia

  • ≥8 or 25% increase
    • Allopurinol
      • Acts slowly; only helpful for preventing future production of uric acid
      • 10mg/kg/d PO q8 OR 200-400 mg/m2 IV q12; renally dosed
      • Inhibition of xanthine oxidase can last 18-30h
    • Urate Oxidase Rx
      • Rasburicase 0.05-0.2mg/kg IV)
      • Can be used for BOTH prevention and treatment
      • Uric acid final product of purine metabolism
        • Urate oxidase converts uric acid to allantoin (5-10x more soluble)

Hyperkalemia

  • Only give Ca for cardiovascular instability (e.g.ventricular arrhythmias, widened QRS)
    • Giving Ca leads to increased Ca/phos deposition which leads to renal failure
  • See Hyperkalemia for treatment options

Dialysis (Criteria)

  1. K >6
  2. Significant renal insufficiency (Cr >10)
  3. Uric Acid >10
  4. Symptomatic hypocalcemia
  5. Serum phosphorus >10
  6. Volume overload

Disposition

  • Admit (often to ICU)

Source

  • Tintinalli
  • EM Practice March '10
Retrieved from "https://www.wikem.org/w/index.php?title=Tumor_lysis_syndrome&oldid=16091"